Aortic Stenosis: Can Lp(a) Treatment Slow Valve
Quick Facts
Why Might Lowering Lp(a) Help Aortic Stenosis?
Aortic stenosis develops when the valve controlling blood flow out of the heart becomes narrowed. Calcium accumulation can stiffen its leaflets, increasing the effort needed to pump blood. The European Atherosclerosis Society's consensus statement identifies substantial genetic and epidemiological evidence linking elevated Lp(a) with calcific aortic valve disease. Lp(a) also carries oxidized phospholipids that may contribute to inflammation and calcification. These findings provide a biological rationale for treatment research, but they do not establish that lowering Lp(a) will reverse existing valve damage. [European Atherosclerosis Society consensus](https://esc365.escardio.org/journal/535).
The distinction matters following Novartis's September 4 announcement that pelacarsen did not meet the primary cardiovascular endpoint in the separate Lp(a)HORIZON trial, despite lowering Lp(a). That study assessed events including heart attacks and strokes. The valve trial addresses a different disease process and outcome; its result cannot be inferred directly from HORIZON. Equally, the valve hypothesis should not be presented as an established benefit after the cardiovascular setback. [Novartis HORIZON announcement](https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd).
What Is the Pelacarsen Aortic Valve Trial Testing?
Lp(a)FRONTIERS CAVS, registered as NCT05646381, is a randomized, double-blind phase 2 study. Novartis's listing, last updated June 23, specifies 502 planned participants and once-monthly injections. Eligibility includes age 50 to under 80, mild or moderate calcific aortic stenosis, and Lp(a) of at least 175 nmol/L. Severe stenosis is excluded. Participants must also receive appropriate treatment for existing cardiovascular risk factors. These criteria describe the research population, rather than a recommendation to prescribe the experimental medicine. [Novartis trial listing](https://www.novartis.com/clinicaltrials/study/nct05646381).
Pelacarsen is an antisense oligonucleotide designed to reduce production of Lp(a). The central clinical question is whether that biological effect changes the course of valve disease with acceptable safety. Investigators must distinguish a lower blood measurement from meaningful slowing of stenosis. Even an encouraging phase 2 result would need careful interpretation before concluding that treatment could delay valve replacement or improve survival. The available study description establishes what researchers intend to test; it does not demonstrate effectiveness. [Pelacarsen mechanism](https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd).
How Is Aortic Stenosis Treated While Drug Research Continues?
People with aortic stenosis need follow-up tailored to disease severity, often including echocardiography to assess valve function and the heart's response. Medicines can treat accompanying problems such as hypertension or fluid retention, but patients should not assume that these treatments remove valve calcium. New breathlessness, chest discomfort, dizziness or declining exercise tolerance warrants prompt assessment. The American Heart Association emphasizes regular monitoring even when symptoms are absent. [AHA guidance on managing aortic stenosis](https://www.heart.org/en/health-topics/heart-valve-problems-and-disease/heart-valve-disease-risks-signs-and-symptoms/managing-aortic-stenosis-symptoms).
When intervention is indicated, treatment may involve surgical valve replacement or transcatheter aortic valve implantation, also called TAVI or TAVR. The ESC/EACTS guidelines emphasize assessment by a multidisciplinary Heart Team, considering anatomy, other illnesses, life expectancy and patient preferences. Experimental Lp(a) treatment should not delay a recommended valve procedure. The potential contribution of drug research is to establish whether earlier treatment can alter disease progression before advanced obstruction develops. [ESC/EACTS valve disease guidance](https://www.escardio.org/news/news-room/congress-news/2025-guidelines-valvular-heart-disease/).
Frequently Asked Questions
No. Its use for calcific aortic stenosis is investigational. The trial is designed to determine whether it can slow progression with acceptable safety.
No. Elevated Lp(a) is a risk factor, not a diagnosis of valve narrowing. Aortic stenosis is assessed through clinical evaluation and imaging, usually echocardiography.
No. An experimental treatment with unproven benefit should not postpone a clinically indicated valve procedure. Treatment timing should be discussed with the cardiology team.
References
- Novartis. Lp(a)FRONTIERS CAVS: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis. NCT05646381. Updated June 23, 2026.
- European Atherosclerosis Society. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022.
- Novartis. Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD). September 4, 2026.
- American Heart Association. Managing Aortic Stenosis Symptoms. Reviewed June 15, 2026.
- European Society of Cardiology and European Association for Cardio-Thoracic Surgery. 2025 ESC/EACTS Guidelines for the management of valvular heart disease.